Real-world data demonstrates that a subset of node-negative (N0) breast cancer patients with high-risk features has a recurrence and mortality rate nearly identical to that of node-positive (N1) patients. This finding justifies intensifying adjuvant therapy with agents like CDK4/6 inhibitors for this seemingly lower-risk group, as was done in the NATALEE trial.

Expert clinicians select genomic assays with nuance. For a patient where a low-risk result is desired to avoid chemotherapy, Oncotype DX may be chosen as it tends to yield more low-risk scores. Conversely, MammaPrint may be used for a chemo-hesitant patient, as it is more likely to return a high-risk result.

Trials like TaylorX and MINDACT use genomic scores to identify patients with early-stage, HR+/HER2- breast cancer who won't benefit from adjuvant chemotherapy. This avoids significant toxicity for two-thirds to over 80% of patients who would have received it under older guidelines, without compromising their outcomes.

Data from the FLEX registry trial, supported by propensity score matching, indicates the survival benefit of adding anthracycline (Adriamycin) to chemotherapy is confined to patients with a MammaPrint High 2 (ultra-high risk) score. Patients in the High 1 group saw no additional benefit.

Data from the Optima trial shows the ProSigna (PAM50) gene signature can identify premenopausal ER+ breast cancer patients, even those with high nodal burden, who can safely forgo chemotherapy. For those with a low-risk score, adequate ovarian suppression alone provides sufficient benefit, marking a major step in treatment de-escalation.

For premenopausal patients with extensive nodal disease (e.g., N2), the clinical indication for chemotherapy is so strong that even a low-risk genomic score would not be enough to withhold treatment. This highlights the primacy of clinical staging over genomic data in certain high-risk scenarios.

Contrary to the belief that HR+ breast cancer primarily carries a late recurrence risk, data shows high-risk, node-positive patients can be extremely aggressive early on. With recurrence rates up to 29.1% within five years, this subgroup can perform as poorly, or even worse, than triple-negative breast cancer, highlighting the need for intensive adjuvant therapy.

For patients with 1-3 positive nodes and low-risk biology (e.g., low-grade lobular, low recurrence score), experts are comfortable deferring chemotherapy. This challenges traditional node-based risk assessment, prioritizing tumor biology to avoid unnecessary toxicity in otherwise high-risk patients.

Oncotype DX risk scores are more influenced by estrogen-related genes, while other assays like MammaPrint are driven more by genes related to cell proliferation. This fundamental difference in their underlying biology can inform an oncologist's choice of which genomic test is most appropriate for a given patient's tumor.